Skip to search formSkip to main contentSkip to account menu

Bromodomain Inhibitor ABBV-075

Known as: ABBV-075 
An inhibitor of one or more as of yet undisclosed bromodomain (BRD)-containing protein(s), with potential antineoplastic activity. Upon… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
PF254 RESULTS FROM THE FIRST-IN-HUMAN STUDY OF MIVEBRESIB (ABBV-075), A PAN-INHIBITOR OF BROMODOMAIN AND EXTRA TERMINAL PROTEINS, IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
Review
2018
Review
2018
Abstract DDT01-05: ABBV-744: A first-in-class highly BDII-selective BET bromodomain inhibitor
  • W. Kati
  • Cancer Chemistry
  • 2018
  • Corpus ID: 81338181
The BET family of proteins consists of BRD2, BRD3, BRD4 and BRDT, with each of these proteins containing two distinct… 
Review
2016
Review
2016
Abstract 4695: Functional group elaboration of a low molecular weight fragment to yield the novel BET family bromodomain inhibitor ABBV-075
Phenotypic cell-based screening assays combined with affinity chromatography and mass-spectrometry identified the BET family of… 
2016
2016
Abstract 4706: ABBV-075 exhibits robust in vitro and in vivo activities against the ABC and GCB subtypes of DLBCL
Diffuse Large B-Cell Lymphoma (DLBCL) consists of activated B-cell-like (ABC), germinal center B cell-like (GCB), and primary… 
Review
2016
Review
2016
Abstract 4692: Targeting the BET bromodomain proteins and anti-apoptotic protein BCL2 in small cell lung cancer
10% to 15% of all lung cancers are small cell lung cancer (SCLC), named for the size of the cancer cells when seen under a… 
2016
2016
Abstract 3085: The BET family bromodomain inhibitor ABBV-075 targets multiple pathogenesis factors in multiple myeloma and exhibits robust in vivo efficacies as a single agent and in combination with…